Family history and colorectal cancer
Family history can determine your cancer risk. About one in four colorectal cancer patients have a family history of colorectal cancer.
It runs in the family: colon cancer genetics
In this webinar we cover everything from what it means to have a cancer family history to the importance of talking with your healthcare provider.
What is your background?
About one in four colorectal cancer patients have a family history of colorectal cancer.
A family history of colorectal cancer means any of the following are true:
- At least one immediate family member (parent, brother, sister, child) was diagnosed under the age of 60.
- Multiple second-degree relatives (grandparents, aunts, uncles, etc.) were diagnosed with colorectal cancer or advanced polyps (risk increases if diagnosed before the age of 45).
Inherited conditions
About 5-7% of colorectal cancer patients inherited a gene mutation that greatly increased their lifetime risk.
These mutations include:
Genetic factors
These genetic factors also increase your lifetime risk of being diagnosed with colorectal cancer:
- You have a cluster of family members diagnosed with colorectal cancer, referred to as familial colorectal cancer.
- You inherit a harmful DNA mutation from a parent. This impacts approximately 5-7% of all colorectal cancer patients.
Family history and screening
People with a family history of cancer should getscreened atage 40 or 10 years before the youngest case in your immediate family, whichever is earlier.
Talk to your family and learn your family history. Then share that information with your doctor.
Genetics and your risk
Genetic and Inherited ConditionsTop resources
Statement: SCOTUS Decision in Kennedy v. Braidwood Management, Inc.
The Colorectal Cancer Alliance applauds the Supreme Court’s decision in Kennedy v. Braidwood, preserving no-cost preventive care under the ACA—including lifesaving colorectal cancer screenings.
2025 ASCO update: Six big studies
The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.
Hope in the Details: How Heather’s Biomarker Opened New Treatment Paths
After a stage IV colorectal cancer diagnosis, Heather’s biomarker test revealed a critical mutation — opening the door to clinical trials and new hope.